LG
Company
LG develops one asset, in phase 3 (gemigliptin/dapagliflozin/metformin in type 2 diabetes). Mostly small molecule acting on AMPK signalling, SLC5A2 and DPP4.
- 1
- Asset
- Furthest stage
- Phase 3
- 10
- Trials
- 0
- Signals
Pipeline
1gemigliptin/dapagliflozin/metformin
Fixed-dose combination of DPP-4 inhibitor, SGLT2 inhibitor, and biguanide for glycemic control.
Phase 3, Small molecule, AMPK signalling, SLC5A2, type 2 diabetes, fasting (Phase 1)
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
11 asset, 10 trials
In the full profile
- Evidence behind the mechanisms4
- Trials11
- Signals3
- Similar companies6